What is Divis Laboratories Ltd's PE ratio?

Divis Laboratories Ltd trades at a P/E ratio of 73.40.

What is Divis Laboratories Ltd's market cap?

Divis Laboratories Ltd's market capitalisation is ₹1.92L Cr.

When are Divis Laboratories Ltd's next results?

Divis Laboratories Ltd's next earnings date is 1 Aug '26.

What is Divis Laboratories Ltd's ROE?

Divis Laboratories Ltd's return on equity (ROE) is 16.5%.

What sector is Divis Laboratories Ltd in?

Divis Laboratories Ltd (DIVISLAB) is classified in the Healthcare sector (Pharmaceuticals).

Healthcare · Pharmaceuticals

Divis Laboratories Ltd (DIVISLAB)

₹7,248.50

Mkt cap

₹1.92L Cr

P/E ratio

73.40

P/B

11.49

Div yield

0.41%

ROE

16.50%

ROCE

22.00%

EPS (TTM)

₹98.75

Book value

₹631

52W range

5,690–7,387

Sector

Healthcare

Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients [1]

NSE DIVISLABBSE 532488www.divislabs.com

Health check

Constructive

ValuationExpensive

ProfitabilityStrong

GrowthModerate

TechnicalsBullish

52-week range

−1.87% from high

₹7,249

₹5,690+27.40% from low₹7,387

Current

₹7,248.50

Prev close

₹7,220.00

Day

+0.39%

Price performance

+0.39%

−0.95%

+7.97%

+13.94%

+20.55%

+6.74%

YTD

+13.39%

Financials

F

Revenue, profit & margin

P/E ratio

73.4×

DIVISLAB is 116% above the sector median of 33.9×

DIVISLAB73.4×

Sector median33.9×

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	1,951	1,778	1,909	1,855	2,303	2,118	2,338	2,319	2,585	2,410	2,715	2,604	2,831
Expenses	1,464	1,274	1,430	1,366	1,572	1,496	1,622	1,576	1,699	1,681	1,827	1,714	1,897
Operating Profit	487	504	479	489	731	622	716	743	886	729	888	890	934
OPM %	25%	28%	25%	26%	32%	29%	31%	32%	34%	30%	33%	34%	33%
Other Income	66	81	86	95	79	79	106	82	86	119	145	14	155
Interest	0	0	1	0	2	0	1	0	1	3	8	6	6
Depreciation	87	93	95	95	95	97	99	99	107	112	113	118	120
Profit before tax	466	492	469	489	713	604	722	726	864	733	912	780	963
Tax %	31%	28%	26%	27%	25%	29%	29%	19%	23%	26%	24%	25%	22%
Net Profit	321	356	348	358	538	430	510	589	662	545	689	583	751
EPS in Rs	12.09	13.41	13.11	13.49	20.27	16.20	19.21	22.19	24.94	20.53	25.95	21.96	28.29
Raw PDF

Earnings

EResults dates & reactions

Next results

1 Aug '26scheduled

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +0.20% · closed higher next day 29 of last 62

	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26†
Broadcast	14 Aug '23◦	6 Nov '23◦	10 Feb '24◦	25 May '24◦	3 Aug '24◦	9 Nov '24◦	3 Feb '25◦	17 May '25◦	6 Aug '25	7 Nov '25	11 Feb '26	27 May '26◦
Earnings day	−0.49%	−0.72%	+2.41%	+3.22%	−3.29%	−0.84%	+3.61%	+4.79%	−4.30%	−3.30%	+3.42%	−1.92%
+1 day	−2.03%	−0.45%	+1.32%	+6.54%	−3.28%	−2.34%	+4.07%	+2.75%	−4.33%	−2.79%	+0.15%	−3.59%
+5 days	−0.71%	+0.86%	+1.95%	+4.84%	−2.01%	−0.82%	+1.06%	+7.29%	−4.81%	−5.40%	+1.75%	−2.57%
+15 days	−0.61%	+8.04%	−4.65%	+10.72%	−1.78%	+5.15%	−2.68%	+5.63%	−4.33%	−5.91%	+3.06%	−0.80%
+30 days	−1.76%	+3.59%	−7.79%	+10.42%	+9.24%	−1.06%	−1.05%	+8.44%	−3.26%	−5.88%	−2.88%	+2.07%
Filing	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	PDF	XBRL	XBRL	XBRL	XBRL

Corporate actions

CLast 6 months

Kind	Value	Ex-date	Record
dividend Dividend - Rs 30 Per Share	30.00	24 Jul '26	24 Jul '26

Shareholding

Sas of Jun 2026

51.88%Promoter

Promoters51.88%

FIIs20.19%0.10

DIIs19.29%0.16

Public8.53%0.08

Government0.09%

Ownership trend

Peers

P7 companies

Valuation vs quality

P/E × ROCE · bubble = market cap

Name	CMP	P/E	Mkt Cap	Div Yld	NP Qtr	Qtr Profit Var	Sales Qtr	Qtr Sales Var	ROCE
Sun Pharma.Inds.	₹1,941.10	37.48	4,65,723	0.82%	2,710	+13.58%	14,612	+12.76%	20.53%
Divi's Lab.	₹7,248.50	73.38	1,92,489	0.41%	751	+13.44%	2,831	+9.52%	21.97%
Torrent Pharma.	₹4,961.50	86.10	1,88,697	0.77%	364	−20.58%	4,197	+41.84%	15.19%
Cipla	₹1,410.60	31.82	1,13,893	0.92%	786	−39.19%	7,119	+2.33%	15.49%
Zydus Lifesci.	₹1,108.70	20.39	1,10,613	0.09%	1,341	+21.92%	7,587	+16.22%	21.14%
Lupin	₹2,370.50	19.06	1,08,401	0.76%	1,469	+101.49%	7,475	+31.89%	29.93%
Mankind Pharma	₹2,507.20	51.44	1,03,559	0.04%	559	+34.23%	3,443	+11.81%	13.53%
Median: 157 Co.	₹432.05	33.93	1,970	0.10%	15	+28.10%	176	+17.66%	15.10%

Filings

D

Annual reports15

Financial Year 2026bse Financial Year 2025bse Financial Year 2024bse Financial Year 2023bse Financial Year 2022bse Financial Year 2021bse Financial Year 2020bse Financial Year 2019bse Financial Year 2018bse Financial Year 2017bse Financial Year 2016bse Financial Year 2015bse Financial Year 2014bse Financial Year 2013nse Financial Year 2013bse

Credit ratings5

Rating update 26 Aug 2025care Rating update 13 Sep 2024care Rating update 12 Sep 2023care Rating update 4 Oct 2022care Rating update 5 Oct 2021care

Announcements5

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 16h - Q1 FY27 unaudited results on August 1, 2026; earnings call at 14:00 IST.Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2026. 20 Jul - Board meeting on August 1, 2026 to approve Q1 FY27 standalone and consolidated results.Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Jul - Newspaper Clippings - Notice of 36th AGM, e-voting & other information Notice Of 36Th Annual General Meeting To Be Held On August 10, 2026 15 Jul Business Responsibility and Sustainability Reporting (BRSR) 15 Jul - Filed FY 2025-26 BRSR, including ESG metrics, SBTi targets, and sustainability performance.